Time to relapse after tildrakizumab withdrawal in patients with moderate-to-severe psoriasis who were responders at week 28: post hoc analysis through 64 weeks from reSURFACE 1 trial.
R B WarrenY José Manuel CarrascosaE FumeroA SchoenenbergerM G LebwohlJacek Cezary SzepietowskiKristian ReichPublished in: Journal of the European Academy of Dermatology and Venereology : JEADV (2020)
When treatment is interrupted, tildrakizumab provides durable maintenance of efficacy with a median time to loss of PASI 75 response of 5-6 months, irrespective of the dose. Interventions on modifiable risk factors for relapse, such as BMI, may improve personalized long-term psoriasis management.